Envestnet Asset Management Inc. Cuts Stake in Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)

Share on StockTwits

Envestnet Asset Management Inc. lessened its position in shares of Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) by 53.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,324 shares of the medical research company’s stock after selling 2,693 shares during the period. Envestnet Asset Management Inc.’s holdings in Bio-Rad Laboratories, Inc. Class A Common Stock were worth $581,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Sivik Global Healthcare LLC increased its holdings in Bio-Rad Laboratories, Inc. Class A Common Stock by 20.0% during the 1st quarter. Sivik Global Healthcare LLC now owns 15,000 shares of the medical research company’s stock worth $3,751,000 after acquiring an additional 2,500 shares during the period. Stevens Capital Management LP increased its holdings in Bio-Rad Laboratories, Inc. Class A Common Stock by 30.6% during the 1st quarter. Stevens Capital Management LP now owns 7,655 shares of the medical research company’s stock worth $1,914,000 after acquiring an additional 1,795 shares during the period. Tamarack Advisers LP bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the 1st quarter worth approximately $9,478,000. Aperio Group LLC increased its holdings in shares of Bio-Rad Laboratories, Inc. Class A Common Stock by 1.2% in the 1st quarter. Aperio Group LLC now owns 19,127 shares of the medical research company’s stock worth $4,783,000 after buying an additional 235 shares during the last quarter. Finally, Synovus Financial Corp increased its holdings in shares of Bio-Rad Laboratories, Inc. Class A Common Stock by 72.6% in the 1st quarter. Synovus Financial Corp now owns 1,674 shares of the medical research company’s stock worth $433,000 after buying an additional 704 shares during the last quarter. 64.12% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Bio-Rad Laboratories, Inc. Class A Common Stock from a “hold” rating to a “sell” rating in a report on Tuesday, May 8th. ValuEngine raised shares of Bio-Rad Laboratories, Inc. Class A Common Stock from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Wells Fargo & Co increased their price target on shares of Bio-Rad Laboratories, Inc. Class A Common Stock from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. Jefferies Financial Group increased their price target on shares of Bio-Rad Laboratories, Inc. Class A Common Stock to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Citigroup increased their price target on shares of Bio-Rad Laboratories, Inc. Class A Common Stock to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Bio-Rad Laboratories, Inc. Class A Common Stock has a consensus rating of “Buy” and an average price target of $297.20.

Shares of Bio-Rad Laboratories, Inc. Class A Common Stock opened at $298.32 on Friday, Marketbeat.com reports. Bio-Rad Laboratories, Inc. Class A Common Stock has a 52-week low of $208.95 and a 52-week high of $304.36. The firm has a market capitalization of $8.94 billion, a PE ratio of 72.76, a price-to-earnings-growth ratio of 3.26 and a beta of 1.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.33 and a quick ratio of 2.99.

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) last announced its quarterly earnings data on Tuesday, May 8th. The medical research company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.10. Bio-Rad Laboratories, Inc. Class A Common Stock had a net margin of 34.32% and a return on equity of 3.84%. The company had revenue of $551.52 million during the quarter, compared to analysts’ expectations of $527.20 million. During the same quarter in the prior year, the company earned $0.68 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. equities research analysts forecast that Bio-Rad Laboratories, Inc. Class A Common Stock will post 6.13 EPS for the current year.

Bio-Rad Laboratories, Inc. Class A Common Stock Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Institutional Ownership by Quarter for Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Class A Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. Class A Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply